Bivalirudin
Direct thrombin inhibitor for PCI anticoagulation. Reversible hirudin analog with rapid onset and offset, ideal for percutaneous coronary intervention and heparin-induced thrombocytopenia (HIT) management.
Bivalirudin is a synthetic 20-amino acid peptide and a direct thrombin inhibitor used as an anticoagulant in percutaneous coronary intervention (PCI) and for the treatment of heparin-induced thrombocytopenia (HIT). It consists of a hirudin-like N-terminal domain that binds to thrombin’s active site and a C-terminal domain that interacts with the fibrinogen recognition exosite, providing rapid and predictable anticoagulation with a short half-life.
| Parameter | Specification |
| CAS | 128270-60-0 |
| Molecular Formula | C₉₈H₁₃₈N₂₄O₃₃ |
| Molecular Weight | 2180.29 g/mol |
| Category | Cardiovascular |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | PCI anticoagulation, HIT, thrombosis prevention, acute coronary syndrome |
| CAS | 128270-60-0 |
|---|---|
| Applications | Ischemic Complication Control, Percutaneous Coronary Intervention, Thrombosis Prevention |
Related products
-
Dulaglutide
CAS: 923950-08-7 -
Degarelix
CAS: 214766-78-6Applications: Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression -
Mazdutide
CAS: 2259884-03-0Applications: metabolic syndrome, Overweight treatment, Type 2 diabetes -
Setmelanotide
CAS: 920014-72-8Applications: Appetite Regulation, Genetic Obesity, MC4R Agonist, metabolic syndrome